INTRA-ARTICULAR TPX-100 SIGNIFICANTLY IMPROVES PAIN MEASURES AND SLOWS PATHOLOGICAL BONE SHAPE CHANGE IN KNEE OA

Abstract

Purpose: TPX-100 is a 23-amino acid peptide derived from Matrix Extracellular Phosphoglycoprotein (MEPE); a small integrin-binding ligand N-linked glycoprotein (SIBLING) family member highly expressed by osteocytes that may play a role in osteoarthritic bone remodeling. Non-clinical data in experimental knee joint injury in large and small animal species and in OA clinical trials support the safety and efficacy of TPX-100 as a potential disease-modifying OA drug. Study TPX-100-5 was designed to examine MRI-based 3-dimensional bone shape changes after IA TPX-100 or placebo in subjects with moderate to severe knee OA; and to investigate associations between bone shape changes and knee pain measures over 12 months.